Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Udenafil in adolescents with Fontan physiology
NCT05918211Phase 3Recruiting
- Sponsor
- Mezzion Pharma
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in single ventricle heart disease (SVD) comparing Udenafil with Placebo (2 arms). Primary endpoint: Peak Minute Oxygen Consumption at 26 weeks. Started Oct 2023; status: recruiting.
02
Drugs
udenafil
03
Conditions
single ventricle heart disease (SVD)
Beyond the preview
Go deeper on NCT05918211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918211.